Diamond Biotechnology (晶鑽生醫) announced the receipt of a €2 million (approx. NT$75 million) milestone payment for its next-generation regenerative injectable, NeoFilera. This is expected to push January revenue past the NT$100 million mark, a record high.

• Strategic Pivot: Chairman Dr. Hsieh Chia-hsien stated that 2025 was a year of restructuring, reducing low-margin equipment distribution to 60% and focusing on high-margin proprietary products (70–80% margin) like regenerative materials and lifting threads.
• Global Distribution: Following a global licensing deal with French aesthetics giant Laboratoires FILLMED, Suneva will recognize a total of €6 million in milestones. FILLMED will manage global distribution (excluding Taiwan and Thailand), with minimum purchase guarantees to provide stable long-term revenue.
• Commercial Timeline:
• 2026: Sales to launch in Indonesia, Japan, and Hong Kong.
• 2027: Targeted approvals and launches in the EU and China (clinical trials currently 50% complete).
• IPO Strategy: The company is evaluating a 2027 IPO listing but may apply as early as late 2026 via the "Technology Enterprise" pathway, citing its R&D, proprietary manufacturing, and international licensing advantages.

Resource: 晶鑽生醫首筆簽約金200萬歐元入帳，今年國際佈局收割，營運拚新高